Company news
Quince Therapeutics, Inc. news in 2024
Quince Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
November 12, 2024
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
August 14, 2024
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
August 12, 2024
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
June 24, 2024
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
June 2, 2024
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
May 12, 2024
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
March 31, 2024
Quince Therapeutics Launches Scientific Advisory Board
February 21, 2024
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
February 14, 2024